Clinical Trials Sponsored by Cantex Pharmaceuticals

Total 87781 results

Tasly Pharmaceuticals, Inc.
Tasly Pharmaceutical Group Co., Ltd

No longer available

Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19

Covid19

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates; Triangle Biostatistics

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States, Spain, Canada, Australia, United Kingdom, Germany, Netherlands, Belgium, Austria, France
Kissei Pharmaceutical Co., Ltd.
JCR Pharmaceuticals Co., Ltd.

Completed

A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

Anemia

Japan
Fox Chase Cancer Center
M.D. Anderson Cancer Center; Teva Pharmaceuticals USA

Completed

Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

United States
Astex Pharmaceuticals, Inc.

Recruiting

A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelocytic Leukemia | Myelodysplastic Syndrome/Neoplasm

United States, Canada
Astex Pharmaceuticals, Inc.

Active, not recruiting

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Relapsed/Refractory Peripheral T-cell Lymphoma

Spain, United States, Australia, France, United Kingdom, Italy, Poland
Astex Pharmaceuticals, Inc.

Active, not recruiting

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Myelodysplastic Syndromes

Spain, United States, Belgium, Canada, Germany, Italy
Astex Pharmaceuticals, Inc.

Terminated

A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Astex Pharmaceuticals, Inc.

Terminated

A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

Acute Myeloid Leukemia | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm

United States, Canada
Astex Pharmaceuticals, Inc.

Completed

SGI-110 in Combination With Carboplatin in Ovarian Cancer (SGI-110)

Ovarian Cancer

Canada, United States, United Kingdom
Astex Pharmaceuticals, Inc.

Completed

SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

AML | MDS | CMML

United States, Canada
Astex Pharmaceuticals, Inc.

Completed

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome | MDS

United States, Canada
Astex Pharmaceuticals, Inc.

Completed

A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029

Healthy Volunteers

United States
Astex Pharmaceuticals, Inc.

Completed

Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors (SGI-0470-02)

Malignant Disease

United States
Astex Pharmaceuticals, Inc.

Terminated

Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma

Prostate Cancer | Non-Hodgkins Lymphoma

United Kingdom, United States
Astex Pharmaceuticals, Inc.

Completed

SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States, United Kingdom, Canada
Astex Pharmaceuticals, Inc.

Terminated

Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia

United States
Astex Pharmaceuticals, Inc.

Unknown

Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer

Pancreatic Cancer

United States
Astex Pharmaceuticals, Inc.

Completed

Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas

Sarcoma | Small Intestine Cancer | Gastrointestinal Stromal Tumor

United States
Henan Cancer Hospital
Qilu Pharmaceutical Co., Ltd.; Beijing Biostar Pharmaceuticals Co., Ltd.

Not yet recruiting

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

HER-2 Negative Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns...
Astex Pharmaceuticals, Inc.

Active, not recruiting

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

Solid Tumor

United States
Astex Pharmaceuticals, Inc.

Unknown

Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Pancreatic Cancer

United States
Astex Pharmaceuticals, Inc.

Completed

Nitrocamptothecin in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Astex Pharmaceuticals, Inc.

Terminated

MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma

Lymphoma | Unspecified Adult Solid Tumor, Protocol Specific

United States
Astex Pharmaceuticals, Inc.

Completed

Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer

Lung Cancer

United States
Astex Pharmaceuticals, Inc.

Completed

Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Breast Cancer

United States
Astex Pharmaceuticals, Inc.

Unknown

Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer

Colorectal Cancer

United States
Astex Pharmaceuticals, Inc.

Unknown

Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas

Pancreatic Cancer

United States
Astex Pharmaceuticals, Inc.

Unknown

Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery

Gastric Cancer | Esophageal Cancer

United States
M.D. Anderson Cancer Center
Janssen Pharmaceutica

Active, not recruiting

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Aggressive Variant Prostate Carcinoma | Metastatic Prostate Neuroendocrine Carcinoma | Metastatic Prostate Small Cell Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Telix Pharmaceutical

Active, not recruiting

Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma

Renal Cancer

United States
Santen Inc.
Vistakon Pharmaceuticals

Completed

Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator

Cataract

United States
Memorial Sloan Kettering Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study

Multiple Myeloma | High Risk Smoldering Multiple Myeloma

United States
M.D. Anderson Cancer Center
Genentech, Inc.; OSI Pharmaceuticals

Completed

Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

Liver Cancer

United States
Fox Chase Cancer Center
Genentech, Inc.; OSI Pharmaceuticals

Completed

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States
Memorial Sloan Kettering Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D

Non-Small Cell Lung Cancer

United States
Memorial Sloan Kettering Cancer Center
Progenics Pharmaceuticals, Inc.

Completed

Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)

United States
Memorial Sloan Kettering Cancer Center
Synta Pharmaceuticals Corp.

Completed

Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer

Breast Cancer

United States
Memorial Sloan Kettering Cancer Center
Synta Pharmaceuticals Corp.

Completed

Clinical and Translational Study of STA-9090

Rectal Cancer | Colon Cancer

United States
Baptist Health South Florida
Miami Cancer Institute; Cantex Pharmaceuticals Inc.

Recruiting

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases (ADORATION)

Cancer | Metastatic Cancer | Metastasis | Brain Metastases | Brain Metastases, Adult

United States
Jina Pharmaceuticals Inc.
Novum Pharmaceutical Research Services; Lambda Therapeutic Research Ltd.; Intas...

Recruiting

Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

Bipolar I Disorder

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

Belgium
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients (EVOLUTION)

Multiple Myeloma

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Austria
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma

Multiple Myeloma

Belgium, France, Germany
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis

Urinary Tract Infections | Pyelonephritis
Johnson & Johnson Pharmaceutical Research & Development...
ALZA; Sequus Pharmaceuticals

Terminated

CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

Ovarian Neoplasms
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma

Multiple Myeloma

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Non-Small Cell Lung Cancer

Belgium
Cancer Prevention Pharmaceuticals, Inc.

Completed

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

Familial Adenomatous Polyposis

United States, Belgium, Germany, Canada, Netherlands, Spain, United Kingdom

Clinical Trials Sponsored by Cantex Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations